Your browser doesn't support javascript.
loading
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh, Issam S; Moore, Donald C; Martin, Allison; Karabinos, Allison; Hill, Hailey; Ndiaye, Ami; Robinson, Jordan D; Paul, Barry A; Atrash, Shebli; Bhutani, Manisha; Voorhees, Peter M; Usmani, Saad Z.
Afiliação
  • Hamadeh IS; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC. Electronic address: Ish_tox@yahoo.com.
  • Moore DC; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Martin A; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Karabinos A; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Hill H; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Ndiaye A; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Robinson JD; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Paul BA; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Atrash S; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Bhutani M; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Voorhees PM; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Usmani SZ; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.
Clin Lymphoma Myeloma Leuk ; 21(7): 470-475, 2021 07.
Article em En | MEDLINE | ID: mdl-33785299
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Guias de Prática Clínica como Assunto / Reação no Local da Injeção / Anticorpos Monoclonais / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Guias de Prática Clínica como Assunto / Reação no Local da Injeção / Anticorpos Monoclonais / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article